1. At a Glance
Astec Lifesciences just reported Q1 FY26 loss of ₹33 Cr, OPM at -12%, and a rights issue of ₹249 Cr at ₹890/share. The stock fell 3.4% to ₹869, continuing its losing streak. Agrochemicals are wilting, and so is investor patience.
2. Introduction
Remember when agrochem stocks were the darling of every rural growth story? Astec is now the kid who missed the bus—negative ROE (-45%), shrinking sales (-6% CAGR), and a rights issue begging for funds.
3. Business Model – WTF Do They Even Do?
- Core: B2B manufacturing of agrochemical active ingredients, intermediates, formulations.
- Export: 24 countries (Europe, Japan, US) with custom synthesis projects.
- Moat? Niche chemistry, but margins are being eaten alive by pricing pressure.
4. Financials Overview
- Q1 FY26 Revenue: ₹91 Cr (YoY -36%)
- Net Loss: ₹33 Cr
- FY25 Net Loss: ₹128 Cr
